China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)
CNY 26.55
(-0.19%)
CNY 26.55
(-0.19%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 468.42 Million CNY | -6.08% |
| 2022 | 643.64 Million CNY | 6.3% |
| 2021 | 552.64 Million CNY | 48.03% |
| 2020 | 436.27 Million CNY | -32.27% |
| 2019 | 631.81 Million CNY | -4.26% |
| 2018 | 667.83 Million CNY | 37.65% |
| 2017 | 490.78 Million CNY | 29.85% |
| 2016 | 378.32 Million CNY | 63.54% |
| 2015 | 228.65 Million CNY | 39.04% |
| 2014 | 162.97 Million CNY | 40.85% |
| 2013 | 116.87 Million CNY | 9.01% |
| 2012 | 107.34 Million CNY | 10.84% |
| 2011 | 96.88 Million CNY | 17.45% |
| 2010 | 82.12 Million CNY | 53.31% |
| 2009 | 52.84 Million CNY | 42.93% |
| 2008 | 37.76 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 158.8 Million CNY | 208.34% |
| 2024 Q3 | 112.59 Million CNY | -48.3% |
| 2024 Q2 | 170.78 Million CNY | 7.59% |
| 2023 Q3 | 157.94 Million CNY | -5.7% |
| 2023 Q2 | 167.48 Million CNY | -4.1% |
| 2023 Q1 | 174.64 Million CNY | 77.41% |
| 2023 FY | - CNY | -6.08% |
| 2023 Q4 | -186.83 Million CNY | -218.3% |
| 2022 Q4 | 98.44 Million CNY | -30.45% |
| 2022 Q1 | 139.87 Million CNY | 0.15% |
| 2022 Q2 | 206.82 Million CNY | 47.87% |
| 2022 FY | - CNY | 6.3% |
| 2022 Q3 | 141.54 Million CNY | -31.56% |
| 2021 Q1 | 127.01 Million CNY | 145.98% |
| 2021 Q4 | 139.66 Million CNY | -9.53% |
| 2021 Q3 | 154.38 Million CNY | 25.78% |
| 2021 Q2 | 122.73 Million CNY | -3.36% |
| 2021 FY | - CNY | 48.03% |
| 2020 FY | - CNY | -32.27% |
| 2020 Q4 | 51.63 Million CNY | -36.75% |
| 2020 Q3 | 81.64 Million CNY | -1.59% |
| 2020 Q2 | 82.96 Million CNY | -38.6% |
| 2020 Q1 | 135.12 Million CNY | 4.26% |
| 2019 Q2 | 151.78 Million CNY | 8.14% |
| 2019 Q4 | 129.6 Million CNY | -5.39% |
| 2019 Q1 | 140.36 Million CNY | -36.99% |
| 2019 FY | - CNY | -4.26% |
| 2019 Q3 | 136.99 Million CNY | -9.75% |
| 2018 Q2 | 156.14 Million CNY | 51.73% |
| 2018 Q4 | 222.75 Million CNY | 67.54% |
| 2018 FY | - CNY | 37.65% |
| 2018 Q3 | 132.96 Million CNY | -14.85% |
| 2018 Q1 | 102.91 Million CNY | -40.19% |
| 2017 FY | - CNY | 29.85% |
| 2017 Q2 | 135.49 Million CNY | 72.07% |
| 2017 Q3 | 85.97 Million CNY | -36.55% |
| 2017 Q1 | 78.74 Million CNY | -32.76% |
| 2017 Q4 | 172.06 Million CNY | 100.13% |
| 2016 FY | - CNY | 63.54% |
| 2016 Q4 | 117.11 Million CNY | 29.23% |
| 2016 Q1 | 44.76 Million CNY | -51.21% |
| 2016 Q2 | 84.18 Million CNY | 88.03% |
| 2016 Q3 | 90.62 Million CNY | 7.65% |
| 2015 Q1 | 28.61 Million CNY | -45.24% |
| 2015 Q3 | 46.22 Million CNY | -27.92% |
| 2015 Q4 | 91.75 Million CNY | 98.5% |
| 2015 Q2 | 64.13 Million CNY | 124.13% |
| 2015 FY | - CNY | 39.04% |
| 2014 Q2 | 28.02 Million CNY | 24.95% |
| 2014 Q1 | 22.43 Million CNY | -51.2% |
| 2014 FY | - CNY | 40.85% |
| 2014 Q4 | 52.25 Million CNY | 48.3% |
| 2014 Q3 | 35.23 Million CNY | 25.71% |
| 2013 Q3 | 17.57 Million CNY | -38.28% |
| 2013 Q4 | 45.96 Million CNY | 161.56% |
| 2013 FY | - CNY | 9.01% |
| 2013 Q1 | 17.4 Million CNY | -52.77% |
| 2013 Q2 | 28.47 Million CNY | 63.63% |
| 2012 FY | - CNY | 10.84% |
| 2012 Q4 | 36.83 Million CNY | 95.72% |
| 2012 Q2 | 14.55 Million CNY | -25.67% |
| 2012 Q3 | 18.82 Million CNY | 29.3% |
| 2012 Q1 | 19.58 Million CNY | -13.27% |
| 2011 Q1 | 18.31 Million CNY | 0.0% |
| 2011 FY | - CNY | 17.45% |
| 2011 Q2 | 19.58 Million CNY | 6.9% |
| 2011 Q3 | 19.87 Million CNY | 1.5% |
| 2011 Q4 | 22.57 Million CNY | 13.59% |
| 2010 FY | - CNY | 53.31% |
| 2009 FY | - CNY | 42.93% |
| 2008 FY | - CNY | 0.0% |